Kornimate/medical-research-clean huggingface dataset:
stroking versus ergon technique in pregnant women

Conditions: Lateral Cutaneous Nerve of Thigh Lesion

Summary: the study will focus on non-invasive management options for radiculopathy and functional activity in 3rd trimester women due to lateral cutaneous femoral nerve study. the findings of this study will help future clinicians to develop management plans for these patients that can include non-invasive and non-pharmacological treatment options like ergon technique and stroking based on their effectiveness. the lateral femoral cutaneous nerve is formed by posterior divisions of the anterior rami of spinal nerves to enter the iliac fossa. it continues into the anterolateral thigh by passing either below or through the inguinal ligament, emerging anterior to the sartorius muscle l2 and l3 in the thigh, it gives rise to two branches, the anterior branch supplies the skin of the anterolateral thigh to the knee and the posterior branch innervates the skin of the lateral aspect of the greater trochanter to the mid-thigh region. it can be compressed due to swelling, trauma or pressure in the surrounding areas. common causes may include: tight clothing, obesity or weight gain, and pregnancy. symptoms may include anterior and lateral thigh burning, tingling, and numbness. it will be a randomized clinical trial aimed to find the comparative effects of stroking and ergon technique on radiculopathy and functional activity in pregnant women. women who meet the inclusion criteria that is they show positive femoral traction test, two point discrimination, light touch and pin prick maneuver will be recruited from surya azeem hospital and jinnah hospital, lahore. two groups will be formed 13 patients will be allocated in each group. before applying the techniques pre treatment reading will taken after that hot pack and tens will be applied as a baseline treatment to both groups while ergon technique will be applied to group a while stroking will be applied to the patients of group b. two sessions per week will be given for 8 weeks. after that post treatment reading will be taken on 8th week. data will be analyzed by using spss for windows version 25


Eligibility criteria:
inclusion criteria: * pregnant ladies during 3rd trimester. * pregnant ladies of age between 30 to 40 years. * primigravida and multigravida ladies. exclusion criteria: * pregnant ladies with any previous hip fracture. * women with high risk pregnancy. * any previous history of disc herniation. * patients with lumbar radiculopathy.

Keywords: numbness thigh pain
seroprevalence of sars-cov-2 in unselected surgical patients: an unicentric, regional study

Conditions: SARS-CoV Infection; Seroprevalence; Covid19

Summary: the investigator analyzed the data of the patients admitted to the surgical department during the period 1st september - 10th december 2020 to estimate the seroprevalence of sars-cov-2 infection in the setting of a non-dedicated covid-19 hospital and in a mild cov-2 incidence area and to evaluate the difference of seroprevalence between spring and fall seasons in a cohort of patients undergoing surgery.


Eligibility criteria:
inclusion criteria: * patient admitted to our unit who had performed sars-cov-2 serologic test exclusion criteria: * age \< 18
the effect of ecmo on the pharmacokinetics of the drugs and their clinical efficacy

Conditions: Hypoxia; Extracorporeal Membrane Oxygenation Complication

Summary: this study will examine the pharmacokinetics of the various, routinely given antibiotics, sedatives, and opioids in patients undergoing venous-venous extra-corporal oxygenation (ecmo). little is known about the distribution and effectiveness of antibiotics in this particular patient population.

patients with severe hypoxia that is refractory to traditional therapies are occasionally placed on venous-venous extracorporal membrane oxygenation (vv ecmo) to provide a bridge during the time when lungs alone cannot provide necessary support. this procedure is gaining prominence but it is largely unknown how medications, especially antibiotics, given to the patient on ecmo is distributed throughout the body as compared to patients without ecmo. since the serum level of medication determines the biological activity of the drug, it is important to know if there is a difference in drug distribution between ecmo and non-ecmo patients. the investigator already collected well-established data on several antibiotics on non-ecmo as a part of fda labeling. the study will help to determine if the concentration of currently prescribed are sufficient enough to reach their intended concentration in the study.

Eligibility criteria:
inclusion criteria: * patient with respiratory failure undergoing ecmo. exclusion criteria: * lack of consent * age less than 18 years old * hematocrit lower than 7

Keywords: hypoxia ecmo antibiotics pharmacokinetics
point of care ketone measurement in the newborn

Conditions: Hypoglycaemia

Summary: low blood sugar levels are common in babies after birth. this may be normal as babies can use other sources of energy. however if a baby does not produce these fuels the brain can be starved of energy and be damaged. measurement of these fuels is not done as part of clinical practice in the newborn. the investigators aim to see whether at the same time as taking the blood sugar level from a heel prick these fuels can be measured in a small drop of blood. at the same time as blood needs to be taken for clinical reasons the study team will to take a drop of blood from 50 babies to see how good the point of care (poc) meters are compared to the laboratory at measuring these fuels. if accurate these poc meters could identifying those at risk from brain damage as well as prevent separation of mothers and babies who are establishing breast feeding.


Eligibility criteria:
inclusion criteria: * infants having blood samples taken for clinical management of glucose control exclusion criteria: -

Keywords: hypoglycaemia
clomifene citrate as first line treatment in in vitro fertilization cycles for patients with lower ovarian reserve

Conditions: Infertility

Summary: women with compromised ovarian reserve requiring in vitro fertilization (ivf) still represent a demanding challenge for clinicians. it has classically been claimed that using higher dosages of gonadotropins may overcome the scarce ovarian responsiveness to hyper-simulation and increase the chances of success. however, scientific evidence supporting this view is scanty and costs are inevitably much higher. in this study, the investigators hypothesized that similar chances of pregnancy may be achieved with a mild stimulation using exclusively clomiphene citrate (cc).


Eligibility criteria:
inclusion criteria: * age 18-42 years * infertility status * day 3 serum fsh \> 12 iu/ml in at least two occasions or previous poor response (≤3 oocytes retrieved) to hyper-stimulation exclusion criteria: * contraindications to infertility treatments or pregnancy

Keywords: ovarian reserve ovarian stimulation clomifene citrate high doses follicle stimulating hormone (fsh)
substance dependent teens - impact of treating depression study 1 - 1

Conditions: Alcohol-Related Disorders; Marijuana Abuse; Substance-Related Disorders

Summary: the purpose of this study is to evaluate the impact of treating depression on substance dependent teens.

the primary study aim is to determine whether fluoxetine + cbt is a more effective treatment than placebo + cbt for substance outcomes, depression, and behavior problems. the current community standard of care often withholds pharmacotherapy for depression in substance abusing adolescents, since it is often assumed that their depressions may remit with sud treatment alone. however, this is an untested hypothesis in adolescents and one that we propose to test in the current study.

Eligibility criteria:
inclusion criteria: * must have dsm iv non bipolar major depressive disorder (by clinical interview), dsm iv conduct disorder, and non-tobacco substance disorder. exclusion criteria: * history of or current psychosis, history of psychotic depression, bipolar disorder i or ii, family history of first degree relative with bipolar i, lifetime history of non-substance induced mania/hypomania * unstable chronic or serious medical illness * currently pregnant * take psychotrophic medication, past 2 months: medication or treatment for depression, clinically significant laboratory abnormality

Keywords: alcohol dependence marijuana dependence
prime: panitumumab randomized trial in combination with chemotherapy for metastatic colorectal cancer to determine efficacy

Conditions: Metastatic Colorectal Cancer

Summary: the purpose of this study is to determine the treatment effect of panitumumab in combination with folfox compared to folfox alone as first line therapy for metastatic colorectal cancer


Eligibility criteria:
inclusion criteria: * man or woman at least 18 years old * diagnosis of metastatic colorectal cancer * at least 1 uni-dimensionally measurable lesion of at least 20 mm per modified recist * eastern cooperative oncology group (ecog) performance status of 0, 1, or 2 * paraffin-embedded tumor tissue from the primary tumor or metastasis available for central analyse exclusion criteria: * history or known presence of central nervous system (cns) metastases * history of another primary cancer, except: curatively treated in situ cervical cancer, or curatively resected non-melanoma skin cancer, or other primary solid tumor curatively treated with no known active disease present and no treatment administered for ≥ 5 years before randomization * prior chemotherapy or systemic therapy for the treatment of metastatic colorectal carcinoma except: adjuvant fluoropyrimidine-based chemotherapy or prior fluoropyrimidine therapy administered solely for the purpose of radiosensitization * prior oxaliplatin therapy * prior anti-epidermal growth factor receptor (egfr) antibody therapy (eg, cetuximab) or treatment with small molecule egfr inhibitors (eg, erlotinib) * clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) 1 year prior to randomization history of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest computed tomography (ct) scan * active inflammatory bowel disease or other bowel disease causing chronic diarrhea (defined as \> common terminology criteria (ctc) grade 2 \[ctcae version 3.0\]) * peripheral sensory neuropathy with functional impairment

Keywords: oncology cancer metastatic colorectal cancer egfr panitumumab clinical trail amgen
umblical artery systolic \diastolic ratio and amniotic fluid index in prediction of fetal outcome in term pregnancy

Conditions: Umblical Artery Doppler in Term Pregnancy

Summary: antepartum fetal surveillance is the cornerstone of management in pregnancy. \[1\] it is done primarily to reduce the incidence of adverse fetal outcomes. it minimizes morbidity by optimizing the timing of delivery. fetus at risk of chronic hypoxia is identified and unnecessary interventions are avoided. however, fetal surveillance acts as a diagnostic modality to detect the influence of maternal, placental, and fetal factors on the fetus. the timely detection of morbid changes in the fetal status followed by adequate interventions to avoid death or disability is one of the most important objectives of prenatal care. \[2\] tests now commonly done for antepartum fetal surveillance are nonstress test (nst), amniotic fluid index (afi), biophysical profile, doppler study of umbilical artery (ua), and middle cerebral artery (mca).\[3 6\] however, afi and ua doppler velocimetry both form an essential part of the antenatal surveillance in the assessment of fetal well being. ua doppler is a powerful tool that allows the obstetrician to follow a sequence of fetal hemodynamic events that happen in response to placental insufficiency. \[7\] however, several studies have reported higher sensitivities and specificities for ua doppler ratio for prediction of fetal prognosis. \[3 6\] amniotic fluid is the product of complex and dynamic fetal and placental physiologic processes. disruption of the fine balance may result in overproduction or underproduction of fluid. liquor adequacy often reflects the fetal status. oligohydramnios is associated with increased perinatal loss. furthermore, other studies indicate that ua velocimetry is a predictor of adverse outcomes in pregnancies complicated by oligohydramnios. \[8,9\] thus, arterial doppler velocimetry measurement may be useful in predicting adverse pregnancy outcomes adjunct to other antenatal surveillance tests, especially the afi. therefore, the present study will be done to evaluate the comparative assessment of ua ratio and afi in predicting adverse perinatal outcomes.


Eligibility criteria:
inclusion criteria: * \* age of mother 18-40 years * term pregnancy (37w6d -40w) * singleton pregnancy exclusion criteria: * \*multiple pregnancy * preterm pregnancy before 37w * preeclampsia * iugr * diabetic * congenital anomalies of fetus
study of hlx22 in combanition with trastuzumab and chemotherapy versus placebo in combination with trastuzumab and chemotherapy for treatment of locally advanced or metastatic gastric cancer

Conditions: Gastric Cancer

Summary: the purpose of this study is to evaluate the clinical efficacy and safety of hlx22 in the her2+ locally adanved or metastatic gastric cancer as the first-line therapy.this study consists of three periods, screening period (28 days), treatment period and follow-up period (including safety follow-up, survival follow-up).subjects can be enrolled into this study only if they meet inclusion criteria and do not meet exclusion criteria. the enrolled subjects will receive an intravenous infusion of hlx22/placebo and soc(standard of care: trastuzumab + xelox) once every 3 weeks until the loss of clinical benefit, death, intolerable toxicity, withdrawal of informed consent or other reasons as specified in the protocol(whichever occurs earlier).

hlx22(25mg/kg) or hlx22(15mg/kg) or placebo will be administered intravenously \[iv\] on day 1 of each 3-week cycle. trastuzumab (8 mg/kg loading dose, 6 mg/kg maintenance dose) will be administered iv on day 1 of each 3-week cycle. soc chemotherapy is xelox (1000 mg/m\^2 capecitabine administered orally twice daily \[bid\] on days 1-14 of each 3-week cycle and 130 mg/m\^2 oxaliplatin administered iv on day 1 of each 3-week cycle).

Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of previously untreated, locally advanced unresectable or metastatic her2 positive gastric adenocarcinoma. * her2-positive defined as either immunohistochemistry (ihc) 3+ or ihc 2+ in combination with in-situ hybridization positive (ish+) or fluorescent in-situ hybridization (fish), as assessed by central review on primary or metastatic tumor * has measurable disease as defined by recist 1.1 as determined by the irrc * has a performance status of 0 or 1 on the eastern cooperative oncology group (ecog) performance scale * has a life expectancy of greater than 6 months * has adequate organ function exclusion criteria: * has a known additional malignancy that is progressing or has required active treatment within the past 2 years * has history of her2 targeted therapy * has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the participant's participation for the full duration of the trial, or is not in the best interest of the participant to participate, in the opinion of the treating investigator * is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 7 months after the last dose of trial treatment
use of fish oils to reduce recurrence of atrial fibrillation following dc cardioversion

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to investigate whether fish oil supplements may be beneficial in preventing the recurrence of atrial fibrillation after cardioversion. atrial fibrillation is a heart condition which can sometimes be successfully treated by a cardioversion. cardioversion involves resetting the heart back to normal with the use of electric current. there is a tendency for the atrial fibrillation to recur , days weeks or even months after the cardioversion. fish oil supplements may be of benefit to patients with heart problems recent evidence suggests that fish oils may be beneficial to patients with rhythm disturbances.


Eligibility criteria:
inclusion criteria: * patients with persistent atrial fibrillation on warfarin. exclusion criteria: * paroxysmal atrial fibrillation with self terminating episodes. * left atrial size\>6.0cm * myocardial infarction in the previous 6 months. * contraindications to amiodarone use . * cardiac surgery in the previous 3 months . * an acute reversible illness contributing to the development of af * a qtc interval \> 480ms. * pregnancy
study evaluation the efficacy and safety of vardenafil in subjects with erectile dysfunction for 10 weeks

Conditions: Erectile Dysfunction

Summary: the aim of this international study was to determine if 10 weeks of flexible-dose vardenafil therapy demonstrates superior efficacy compared to the dummy drug (placebo) in erectile dysfunction subjects of a broad etiology when dosed 8 (+/-2) hours prior to sexual intercourse. in addition it should have been determined, if subjects with ed from a broad etiology can tolerate 10 weeks of flexible-dose vardenafil therapy when dosed 8(+/-2) hours prior to sexual intercourse.


Eligibility criteria:
inclusion criteria: * men \>/= 18 years of age, with 6 months or longer diagnosis of ed as defined by nih consensus statement, * history of unresponsiveness to sildenafil * stable sexual relationship for \> 6 month. exclusion criteria: * primary hypoactive sexual desire * history of myocardial infarction, stroke or life-threatening arrhythmia within prior 6 month * nitrate therapy.

Keywords: erectile dysfunction vardenafil
study evaluating venlafaxine er in children and adolescents with social anxiety disorder

Conditions: Social Anxiety Disorder

Summary: to determine the anxiolytic efficacy, safety, and tolerability of a flexible-dose of venlafaxine extended release (er) administered for 16 weeks in the treatment of children and adolescent outpatients with social anxiety disorder (generalized) in a placebo-controlled study.


Eligibility criteria:
inclusion criteria: * male or female outpatient * 8-17 year old * diagnosis of social anxiety disorder exclusion criteria: * concomitant psychiatric or medical disorders which interfere with safety or assessment

Keywords: social anxiety children disorders
ultrasound imaging based on ultrasound bronchoscopy in respiratory diseases: a retrospective, single-center, confirmatory study

Conditions: Benign and Malignant Lymph Nodes

Summary: abstract background and objective: to establish a ultrasound radiomics machine learning model based on endobronchial ultrasound (ebus)to assistdoctors in distinguishing between benign and malignant diagnoses ofmediastinal and hilar lymph nodes. methods: the clinical and ultrasonic image data of 197 patients wereretrospectively analyzed. the radiomics features were extracted by ebus.based radiomics and dimensionality reduction was performed on thesefeatures by the least absolute shrinkage and selection operator (lasso)ebus-based radiomics model was established by support vector machine(svm).205 lesions were randomly divided into a training group (n=143)and a validation group (n=62). the diagnostic efficiency was evaluated byreceiver operating characteristic (roc).results: a total of 13 stable features with non-zero coefficients wereselected. the support vector machine (sv) model exhibited promisingperformance in both the training and verification groups. in the traininggroup, the svm model achieved an area under the curve (auc) of 0.892(95% ci: 0.885-0.899), with an accuracy of 85.3%, sensitivity of 93.2%and specificity of 79.8%.in the verification group, the svm modeldemonstrated an auc of 0.906 (95% c: 0.890-0.923),along with anaccuracy of 74.2%,sensitivity of 70.3%, and specificity of 74.1% conclusion:ebus-based radiomics model can be used to differentiatemediastinal and hilar benign and malignant lymph nodes. the svm modeldemonstrates superiority and holds potential as a diagnostic tool in clinical practice


Eligibility criteria:
inclusion criteria: * (1)chest ct showing enlarged mediastinal or hilar lymph nodes or positive findings of mediastinal and hilar lymph nodes on pet/ct (suv≥2.5); (2)patients who underwent ebus-tbna examination; (3)no contraindications for surgery. exclusion criteria: * (1)prior treatment of target lymph nodes before ebus-tbna; (2)unclear diagnostic results; (3)loss to follow-up.

Keywords: mediastinal and hilar lymph nodes benign and malignant endobronchial ultrasound-based radiomics distinguishing support vector machine
diagnostic interest of leukocyte immunophenotyping using multiparameter 8-color flow cytometry in heart surgery

Conditions: Cardiac Surgery

Summary: in septic patients, septiflux1 study identified immature granulocytes which may have a diagnostic and prognostic interest. however, with these preliminary results it is not possible to make a difference between what is linked to the infection and what is a consequence of the inflammation which goes along with the septic process. using flow cytometry, the study of leukocytes in a pure inflammatory model such as cardiopulmonary bypass in heart surgery could make possible to test the diagnostic interest of the immature granulocytes but also to attribute a prognostic value for the occurrence of post-operative infections.

expression of cd10, cd16, cd24, cd64 on granulocytes, of cd14 and cd16 on monocytes and of cd3 on t lymphocytes. flow cytometers will all be calibrated the same way using common reagents (known fluorescent calibration beads). moreover, cd45 and cd3 level of expression on lymphocytes will help to check that the collection of data is standardized between the different centers.

Eligibility criteria:
inclusion criteria: * patient older than 18 years old * patient undergoing planned heart surgery with cardiopulmonary bypass exclusion criteria: * pregnancy, * progressive solid cancer, * hiv infection, * history of blood or inflammatory disease, * long-term immunosuppressive treatment, * urgent surgical intervention, * documented preoperative infection

Keywords: cardiac surgery infectious complication